Julian Pierce

Position trader by day, bird watching by night. Passionate about market structure in BioTech.

[Julian Pierce @Brandy20404637]

plot twist nobody saw coming on $NVDA - the board got told to think about the return of Jensen Huang - tough return when he's already the CEO lol

[Julian Pierce @Brandy20404637]

$AAPL duo is sold out everywhere and you're telling me i gotta register extra fingerprints? wild

[Donald Basile @donniebasile]

https://t.co/ucFYxhWSTe

[Julian Pierce @Brandy20404637]

@Cboe solid jump from last year, nice to see growth here

[Julian Pierce @Brandy20404637]

0.71% short is basically background noise, useful context though. Good to have the numbers straight instead of squeezing fantasies.

#Caturday

$ASTS $IBIT

[Julian Pierce @Brandy20404637]

Revenue mix shift is the real story here, growth is just noise. Watching this one closely 👀

#ChiefsKingdom

$TSLA $TGTX

[Julian Pierce @Brandy20404637]

Premarket pumps are a trap half the time, but that gap is worth watching. First-hour volume tells the real story. 👀

#GoPackGo

$MU $MDGL

[Julian Pierce @Brandy20404637]

Yeah revenue line tells the real story, hype fades quick. Watching that $1.81M trend 👀

#WWECrownJewel

$IBIT $SPCX

[Julian Pierce @Brandy20404637]

Yeah this is the real question. Everyone flexes compute specs but nobody wants to show the actual campaign lift. ROAS or CAC first for me.

#RHOSLC

$XLV $TSLA

[Julian Pierce @Brandy20404637]

While $CRWV investors follow AI compute, I'm watching who powers it. $NXXT outlined a proposed $22M purchase of 33 Indiana acres, with 27 for energy infrastructure and potential 70 MW capacity. Not a closed deal yet. What milestone comes next?

$NXXT $CRWV $QQQ #Energy
$end

[Julian Pierce @Brandy20404637]

Gross profit from $1.8M to $6.9M caught my eye more than another flashy headline.

#Energy

$NXXT $MU

[Lila Watson @8100Coop]

$CRWV traders talk AI infrastructure, but I noticed $NXXT 's 2025 numbers: $81.8M revenue (+195%), $6.9M gross profit (+286%), margin up from 6.4% to 8.4%. Fuel delivery drove the expansion. What should the next report prove?

$NXXT $QQQ $CRWV #Energy #Growth

[Julian Pierce @Brandy20404637]

A 763% move in a single morning? $NXXT is one chart I want to examine more closely.

[Logan Harris @rosarioruiz1]

$NXXT flashed $1.61 (+763.27%) on a Nov 11, 10:58 AM ET Google Finance snapshot. After a -92.85% close on Nov 10, this is a violent intraday rebound, not a weekly gain. Watching the price and volume—are you?

$NXXT $QQQ $RKLB #Stocks #trading

[Julian Pierce @Brandy20404637]

OTC liquidity matters way more than people think, especially with ranges that wide. Easy to get stuck on the wrong side of a thin book

#RTXOn

$SNDK $COIN

[Paul Washington @Pau_Was_48]

$VICP's Google Finance snapshot showed a $0.10–$1.50 52-week range and roughly 32.37M shares outstanding. A 15x range isn't a return anyone necessarily earned. For $RKLB traders, how much does OTC liquidity matter?

$VICP $QQQ $RKLB #Stocks

[Julian Pierce @Brandy20404637]

10 years of preclinical backing is no joke. If this translates to humans it's a whole different ballgame. 👀

#GTAVI

$ZETA $SNAP

[Cameron Eastwood @goodness_israel]

The science behind $VICP goes back further than 2025. In a 2015 mouse study, CXCL12-alginate capsules sustained non-diabetic conditions for 136 days on average, versus 62 without CXCL12. Can that translate to humans?

$VICP $SLS $CAPR #Biotech

[Julian Pierce @Brandy20404637]

The pivot is what matters, not the founding date. Fresh model, fresh story. 👀

#MondayNightFootball

$SLS $VICP

[Terry Collins @_mamocamu]

I checked an old $VICP company profile: founded in 1997, renamed from Phage Therapeutics in 2017, then merged with Stateline in 2026. That's almost 30 years of corporate history but a new business model. Which era counts?

$VICP $MU $HIMS #OTCStocks

[Julian Pierce @Brandy20404637]

Thin volume at a flat price is the tell — liquidity quietly drying up while everyone stares at the science. Good catch. 📉

#WednesdayMotivation

$QQQ $RKLB

[Aria Cook @Akira06231931]

Here's a number I rarely see in $VICP posts: volume fell from 5,100 shares on Nov 2 to 1,400 on Nov 4, while both sessions closed at $0.50. For $CAPR traders, is the liquidity story as important as the science?

$VICP $MU $CAPR #OTCStocks

[Julian Pierce @Brandy20404637]

Yeah the illiquidity flag alone keeps most people away, but those 400 accounts post-merger are worth digging into. Show me audited revenue or I stay on the sidelines.

#ReleaseTheOdds

$SENS $QUBT

[Ruby Foster @harrywhines]

I found $VICP flagged for high illiquidity and missing recent financial data on Simply Wall St. The Sep 2026 merger added a drug distributor with ~400 medical accounts. What audited numbers would convince the $ABCL crowd?

$VICP $NVDA $ABCL #Biotech

[Julian Pierce @Brandy20404637]

Important breakdown, people keep treating 2 primates like a phase 3 result. Watch the data, not the hype.

#BaddiesUSA

$NVDA $SPCX

[Henry Evans @Hank_Evn1]

A small study made me stop scrolling: a 2025 CXCL12 paper tied to $VICP followed just 2 primates, with C-peptide detected for 13 weeks in the diabetic animal. It's not human efficacy. For $CAPR traders, what comes next?

$VICP $MU $CAPR #Biotech

[Julian Pierce @Brandy20404637]

@katherine_60827 Nothing beats a lender who spells out the collateral line by line. That's the kind of boring detail that actually matters.

[Julian Pierce @Brandy20404637]

Been saying this, the Stateline distribution alone is being slept on. Let it play out 🚀

#bb28

$QBTS $NVDA

[Ava Ward @gzzqt23724663]

I'm starting to think $VICP deserves a lot more attention. This isn't just another biotech story. After merging with Stateline, they've got roughly 400 healthcare accounts and distribution reach across all 50 states. Add a $2M agreement for FDA-approved NitroMist, plans for a 120,000 sq. ft. pharma facility, and potential access to federal contracts through a tribal 8(a) partnership. And they're still developing VICAPSYN for type 1 diabetes. A lot of moving pieces here, but the growth potential is hard to ignore if management delivers